TickerTalks
Browse all tickers →
TickerTalks›$NRXS
NRNRXS

NeurAxis, Inc.

$NRXS·$95M·Biotechnology·Healthcare
$7.61-0.3%YTD+72.6%1Y+191.6%
Price updated 1h ago
NRNRXS
$NRXSNeurAxis, Inc.
$7.61-0.26%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NRXS on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NRXS — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-18

The move is getting stronger, with heavier trading behind it.

A micro-cap paediatric medical-device maker just crossed a big insurance-coverage milestone — and its stock has tripled over twelve months.

Neuraxis is a small-capitalisation medical-device company focused on non-invasive neuromodulation therapies, primarily aimed at paediatric functional-gastrointestinal conditions. It is a genuinely differentiated story on a very small commercial base, and the recent expansion in insurance coverage is the specific tailwind driving the tape.

  • The financial screen is early-scale: revenue is very small and gross margins are extraordinary at close to eighty-six percent of sales, while free-cash-flow yield sits meaningfully negative — a business still spending faster than it earns while it scales the commercial team.
  • The insurance-coverage news is concrete: a medical-coverage-policy milestone has expanded access by an additional very large multi-million count of covered lives, a real fundamental catalyst that lifts the addressable near-term market rather than just the narrative.
  • Corporate housekeeping is active: an officer transition has been filed with a material corporate event, and the group filed an amendment to a shelf-registration statement — the standard set-up for a story preparing to attract deeper institutional capital.

The next earnings print is the credibility check on whether the expanded insurance coverage is showing up in reported unit shipments; a clean sequential revenue step-up would extend the tape further, while any hiccup would test the multiple hard on a very small underlying base.

What to watch: The next quarterly print for whether expanded insurance coverage translates into unit-shipment growth, and any additional coverage-policy expansions. Insider open-market purchases at these prices would strengthen the setup meaningfully.

On the calendar: Q3 earnings — date pending

no x sentiment

Read the AI verdict on $NRXS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NRXS.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.1%YTD
+42.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-9.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-110%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-145%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
16.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-173%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
85.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.19$-0.32+40.6%
Q1 2026May 12, 2026$-0.18$-0.19+5.3%
Q4 2025Mar 19, 2026$-0.17$-0.21+20.9%
Q3 2025Nov 10, 2025$-0.24$-0.20-20.0%
Next earningsTue, Nov 17·consensus EPS $-0.21

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$1.9M+115.7%85.9%-110%$-0.19$-1.0M
Q1 FY26$1.6M+79.5%86.4%-108%$-0.18$-1.2M
Q4 FY25$968K+27.2%85.4%-177%$-0.16$-1.9M
Q3 FY25$811K+21.7%83.3%-259%$-0.24$-1.4M

Forward consensus

3-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$8.3M$8.3M – $8.3M-$0.76-$0.76 – -$0.761
FY27$19.8M$19.8M – $19.8M-$0.27-$0.27 – -$0.271
FY28$32.7M$32.7M – $32.7M$0.31$0.31 – $0.311

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.76%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+18.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+24.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 9.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.455-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyApr 1Carrico Thomas JoesephCRO, CCO, CPO667 sh$1KBuyApr 1Carrico Brian AllenCEO8.1K sh$16KBuyApr 1Henrichs Timothy RobertCFO7.6K sh$15K
+ 16 other (13 awards · 3 conversions) in window

See when $NRXS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 198-K — Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

Neuraxis, Inc. (NRXS) filed an 8-K on July 24, 2026, disclosing both an officer or director change (Item 5.02) and another material event (Item 8.01); the excerpt shows only the cover page. Neuraxis is a small medical device company focused on vagus nerve stimulation, and concurrent personnel and other-event disclosures could signal a partnership, clearance, or reimbursement development.

S-3/AShelf registrationJul 30S-3/A
AI summary

Neuraxis, Inc. (NRXS) filed Amendment No. 1 to its Form S-3 shelf registration statement (Reg. No. 333-297651) on July 30, 2026, refining its continuous offering registration under Rule 415. The total shelf size and specific security types are not visible in the excerpt. Shelf registration amendments for small medical device companies typically precede an imminent equity offering and represent a dilution risk signal for current shareholders.

S-3Shelf registrationJul 23S-3
AI summary

Neuraxis, Inc. (NRXS) filed an original Form S-3 registration statement on July 23, 2026, establishing a shelf registration under Rule 415 for continuous or delayed securities offerings. The total offering size and security types are not specified in the excerpt. Shelf registrations for small medical device companies signal management's intention to access capital markets opportunistically, representing a dilution risk for current shareholders.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
424B5Prospectus supplement (offering)Apr 21424B5
+ 12 other (2 10-Qs · 2 13Gs · 2 routine 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Livesglobenewswire.com·3d agoNeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conferenceglobenewswire.com·3d agoNeuraxis Gains Nearly 137% in a Year: What's Driving the Stock?zacks.com·4d agoNeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcriptseekingalpha.com·4d agoIs Kodak having a "Kodak moment?" 2 watchlist stocks.zacks.com·7d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $NRXS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport